$BLLN · The Motley Fool · 2026-11-14
BillionToOne 值得买入:其 QCT 平台的单分子计数带来传统诊断普遍无法企及的灵敏度;说话者预计对增长最重要的肿瘤液体活检同比增长 96%,年化规模约 6800 万美元。营收超市场预期约 50%,EPS 超过预期的两倍以上,产前业务收入增长 41%,连续第五个季度实现正的 GAAP 营业利润,同时自由现金流约 900 万美元、现金 5.62 亿美元;12 月中旬推出的微小残留病灶检测是这一肿瘤业务布局的关键。
播放时,YouTube 可能接收设备与播放信息并使用 Cookie。 隐私说明 · Google 隐私政策
逐段跳播
今天视频的最后一只股票,我要讲医疗保健板块的另一家公司,一个也许不太为人所知的名字。我想稍微换换花样。我们有时在评论中看到你们提到我们只谈科技股,所以我想稍微改变一下氛围。我们看看吧。
那么,BillionToOne,它的代码是 BLLN。
For the last stock in today's video, I'll be talking about another name in the healthcare sector, another name that is perhaps a little less well known. I'm trying to change things up a bit.
We sometimes see in the comments that you mention we're only talking about technology stocks, so I'm trying to change the atmosphere a little. We'll see. So, BillionToOne, its symbol is BLLN.
如果你不熟悉它,它当然不是一个所有人都熟悉的名字。他们是一家分子诊断公司。他们的平台围绕一种他们拥有、称之为定量计数模板(QCT)的技术构建。这个平台本质上能够以传统诊断公司通常无法匹敌的灵敏度来检测和测量遗传物质。
If you are not familiar with it, it is certainly not a name familiar to everyone. They are a molecular diagnostics company. Their platform is built around a type of technology they own that they call Quantitative Counting Templates (QCT).
This platform can essentially detect and measure genetic material with a level of sensitivity that traditional diagnostic companies generally cannot match.
Billion2One 将这项技术应用于两条不同的产品线。第一条,也是目前其主要业务,是产前检测。他们拥有美国首个也是唯一一个针对胎儿红细胞和血小板抗原的无创产前检测。第二条是他们在肿瘤学领域的业务,他们目前正在构建一整套液体活检检测,可以通过简单的血液样本检测和监测癌症,而不需要进行手术组织活检。
Billion2One applies this technology across two different product lines. The first, which is currently its leading activity, is prenatal testing. They have the first and only non-invasive prenatal test for fetal red blood cell and platelet antigens in the United States.
The second is their activity in the field of oncology, and they are currently building a whole family of liquid biopsy tests that can detect and monitor cancer through a simple blood sample instead of the need for a surgical tissue biopsy.
肿瘤学是最让我兴奋的领域,我相信它未来对该公司及其增长故事来说将是最重要的。有意思的一点是谈谈 Billion to One 所依赖的平台技术。只是为了解释为什么它有点更独特。
当从孕妇身上抽血时,极少量的胎儿 DNA 会自由漂浮在她的血液中,与她自身大量 DNA 混合在一起。因此,从大得多的 DNA 背景中提取特定而微弱的胚胎信号,是无创胚胎检测的主要挑战。
同样的基本挑战也出现在癌症检测中。例如,肿瘤切除后,可能只剩下少量癌症 DNA 片段,漂浮在数百万个健康片段之中。所以,找到那几个片段,正是微小残留病灶检测真正要做的事。
Oncology is the area that excites me the most, and I believe it will be the most important to the company and its growth story in the future. One of the interesting things is to talk about the platform technology that Billion to One relies on.
Just to explain why it's a bit more distinctive. When blood is drawn from a pregnant woman, a tiny amount of fetal DNA swims freely in her bloodstream, mixed with a much larger amount of her own DNA.
Therefore, extracting a specific and faint embryonic signal from a much larger DNA background is the primary challenge for non-invasive embryonic testing. This same type of basic challenge also appears in cancer tests.
For example, after a tumor is removed, only a handful of cancer DNA fragments may remain, swimming amid millions of healthy fragments. So finding those few fragments is what minimal residual disease tests are really trying to do.
Billion to One 平台的工作原理是给每个 DNA 分子连接一个独特标签,使其能够真正计数这些分子,而不是估算它们的比例。你可以把它想象成称量一袋混合硬币来估算其中硬币数量,与逐一标记并计数每枚硬币之间的区别。
这种精确度,也就是单分子级别的精确度,正是让 Billion2One 能够提供这些高度准确的诊断检测的原因,而一些老牌竞争对手至今还无法提供。
The Billion to One platform works by linking a unique tag to each DNA molecule, enabling it to actually count those molecules rather than estimate their proportion. You can think of it as the difference between weighing a mixed bag of coins to estimate the number of coins in it, versus marking and counting each coin individually.
This precision, that is, precision at the level of a single molecule, is what allows Billion2One to offer these highly accurate diagnostic tests that some established competitors have not yet been able to provide.
这也反映在数字上。他们大约一周前也公布了季度业绩,总收入同比增长约50%,超出市场普遍预期。摊薄每股收益是华尔街预期的两倍多。他们的产前检测收入同比增长41%。肿瘤学收入仍是公司较小但增长最快的部分,同比增长96%,现在年化达到约6800万美元。
本季度他们产生了约900万美元的自由现金流。这是他们连续第五个季度按照公认会计原则实现正营业收入。他们的资产负债表上拥有约5.62亿美元的现金及现金等价物。
This is reflected in the numbers as well. They also announced their quarterly results about a week ago, with total revenue exceeding consensus estimates by about 50% year-over-year.
Diluted earnings per share were more than double what Wall Street had expected. Their revenue from prenatal testing increased by 41% year-on-year. Oncology revenues, which are still a smaller but fastest-growing part of the company, have increased by 96% year-on-year, and now reach an annual rate of about $68 million.
They generated approximately $9 million in free cash flow during the quarter. This was the fifth consecutive quarter in which they achieved positive operating income according to generally accepted accounting principles.
They have approximately $562 million in cash and cash equivalents on their balance sheet.
关于他们的肿瘤学工作,最值得关注的一点是,他们有一项新检测将于12月中旬推出。这是一项用于检测微小残留病灶的检测。本质上,这项检测旨在发现患者肿瘤经手术切除后残留的显微镜下癌细胞痕迹。
它仅是一项基于血液的检测。它从第一天起就适用于所有实体瘤。它将在未来几周内在这里发布。这至关重要,因为他们正努力扩大其范围
One of the most important things to watch regarding their oncology work is that they have a new test that will be launched in mid-December. This is a test to detect minimal residual disease.
Essentially, this test is designed to detect microscopic traces of cancer that remain after a patient's tumor has been surgically removed. It is a blood-based test only. It is available for all solid tumors from day one.
It will be released here in the next few weeks. This is essential as they work to expand their range of